‘How to Sell a Massacre’ an Al Jazeera Investigation into Australia’s One Nation Party and Gun Lobby

  • Australia’s One Nation Party Lobbying the National Rifle Association of America (NRA) for Millions of Dollars
  • One Nation’s Chief of Staff, James Ashby, hoped to secure $US20 million political donations to “own the lower house and the upper house”

DOHA, Qatar, March 25, 2019 (GLOBE NEWSWIRE) -- A three-year undercover operation by Al Jazeera shows officials from the National Rifle Association of America (NRA) advising delegates from an Australian political party on how to roll back strict gun control laws and how to deal with critics following a mass shooting.

Representatives from Pauline Hanson’s One Nation political party were seen seeking millions of dollars in donations from supporters of the U.S. gun lobby in Washington D.C. in order for more guns to flow into Australia. They were coached on how to react if softer gun laws ever led to a mass shooting there.

An NRA media liaison officer said the organization remains silent in the immediate aftermath of a multiple shooting, but then launches an attack on critics: “Offense, offense, offense, which is what the NRA does very well.”

Another media officer recommended smearing advocates of gun control for exploiting a mass shooting that led to the deaths of children:

“How dare you stand on the graves of those children to put forth your political agenda? Just shame them to the whole idea. It’s like if you, if your policy, isn’t good enough to stand on itself, how dare you use their deaths to push that forward.”

An Australian undercover reporter, Rodger Muller, posed as a pro-gun advocate and filmed with concealed cameras during meetings with the NRA. The evidence forms part of a two-hour documentary by Al Jazeera into the U.S. gun lobby entitled “How to Sell a Massacre”.

Al Jazeera’s Investigative Unit infiltrated the U.S. gun lobby to find out how it operates. The unit engaged an Australian undercover reporter, Rodger Muller, to pose as the president of a pro-gun organisation, Gun Rights Australia. 

‘Gun Rights Australia’ claimed to advocate for the repeal of strict gun control laws in Australia that had been introduced following a massacre in the town of Port Arthur in 1996. The Australian gun control legislation led to the destruction of more than 650,000 firearms and has been vigorously opposed by the NRA.

New Zealand’s prime minister, Jacinda Ardern announced the introduction of a similar ban on all military-style assault rifles last week, following the attack on mosques in Christchurch that left 50 dead.

In a series of meetings within the NRA, Muller covertly recorded conversations that revealed concern within the organization over the impact of Australia’s gun control laws on the U.S. at a time of increasing public outrage over mass killings.

Media liaison officer Catherine Mortensen described ghost writing stories for the American media: A lot of the times, we’ll write them for like a local sheriff in Wisconsin or whatever.
They’ll submit it with their name on it so that it looks organic. You know, that it’s coming from that community. But we will have a role behind the scenes.”

NRA staff members said their aim is to promote a simple message that focuses on the public’s fear of being attacked.

“We want to print up stories about people who were robbed, had their homes invaded, beaten or whatever it might be and that could have been helped had they had a gun,” says Lars Dalseide, from the public relations team.

According to Ms. Mortensen: “When you start talking about issues that become too complicated or make them think too hard, you’ve kind of lost it. You want something that they can get to, like the American flag. Oh, my gosh, we all get that one, that’s easy.”

One senior NRA lobbyist told Muller that staffers within the NRA’s Institute for Legislative Action, based in Washington D.C., were bracing for a violent assault from anti-gun protestors:

“We’ve got our armed security guard out front… we don’t have firearms in our office so we all have random weapons in case the guy gets past our security guard. I literally have a ladder to throw out my window. James at the end has a hatchet,” the lobbyist said.

Muller also recorded meetings within affiliated gun lobby groups in which members of the One Nation party said they were seeking up to $US20 million in political donations in the lead-up to Australia’s federal elections.

One Nation’s Chief of Staff, James Ashby, had told Muller that he wanted his meetings with gun lobby groups to be kept secret.

“We need to be mindful that anything in writing can always be tracked and traced and used against you,” Ashby said. “If this gets out, it will f**king rock the boat.”

Peter Charley, Reporter: +61 449 754 933

Al Jazeera Press Office:  | +974 5050 9111

Om GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi